Bristol Myers acquires cell therapy partner 2seventy bio for about $286 million
Bristol Myers Squibb will acquire 2seventy bio for about $286 million in cash, sending the cancer cell therapy maker's shares ...
Bristol Myers to acquire cell therapy partner 2seventy bio in $286M all-cash deal
Abecma is being jointly developed and commercialized in the U.S. as part of a co-development, co-promotion, and profit share ...
Jim Cramer Highlights ‘Multi-Billionaire Dollar’ Catalyst for Bristol-Myers Squibb. Co (BMY)
We recently published a list of Jim Cramer’s Latest Portfolio: Top 10 Stocks to Watch. In this article, we are going to take a look at where Bristol-Myers Squibb. Co (NYSE:BMY) stands against other ...